| *Sponsored
(Nasdaq: AMIX) Drops Major Breaking News (Makes Approx. 60+% Move Before The Bell)
*Get Our Updates Faster—Tap Here To Receive SMS Alerts*
November 17th Greetings, Friend!
Autonomix Medical, Inc. (AMIX) is cranking in pre-market.
Up over approx. 60+% at times ahead of today's opening bell, AMIX continues to hold a top watchlist spot early Monday.
Could this early burst becoming about because of today's major news announcement? Check it out:
Autonomix Medical, Inc. Reports Positive Subgroup Results Demonstrating Sustained Improvements in Quality of Life from Post Hoc Analysis of Pancreatic Cancer PoC Study
EORTC QLQ-C30 subgroup results confirm broad and durable quality-of-life improvements across disease stages and metastasis status, complementing previously reported pain reduction and opioid-free outcomes
Late-stage patients showed substantial improvements, suggesting ablation provided clinically meaningful changes even in advanced severe disease
THE WOODLANDS, TX, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced results from a post-hoc exploratory subgroup analysis of its previously reported first-in-human proof-of-concept study (PoC 1) evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with severe pancreatic cancer pain. The analysis evaluated patient-reported quality-of-life, symptom and functional outcomes as a secondary endpoint of the study using the EORTC QLQ-C30 scale (a validated measure of cancer-specific quality of life) across multiple patient subgroups, including tumor stage and metastatic status. Results from this post-hoc exploratory analysis suggested that Autonomix’s targeted ablation therapy may have produced improvements in symptom burden, functionality, and global quality of life following Autonomix’s targeted ablation therapy.
The analysis also provided new procedural findings that will be used to guide Autonomix’s U.S. clinical trial, which is on track to commence in 2026.
...
“These subgroup findings provide deeper insight into how and why our ablation approach is improving outcomes across varied patient types,” said Brad Hauser, President and Chief Executive Officer of Autonomix. “The fact that patients with late-stage and metastatic disease achieved large, durable improvements in symptoms, function, and global quality of life underscores the broad applicability and real-world impact of our therapy. While this is a retrospective post-hoc analysis with modest patient numbers that will require prospective validation, it will inform our future work in our larger, multicenter U.S. clinical trials.”
...
Read the full article here.
Spend a second reviewing my initial report and consider (Nasdaq: AMIX) for your watchlist. -----
During a time of notable progress in neuro-therapeutic technology, attention could quickly become focused on one company driving innovation in precision nerve-targeted therapies for central and peripheral nervous system conditions.
This organization is reshaping the management of chronic pain and cardiovascular challenges through its proprietary methods for neural modulation and symptom control.
Their solutions are advancing benchmarks across multiple indications, with platforms leveraging intelligent feedback and targeted tissue engagement to deliver meaningful clinical results.
For those with an interest in groundbreaking medical technology, exploring this company further may reveal impressive potential for real-world health impact.
And with a low float under 7Mn and a couple of analysts forecasting potential upside exceeding triple-digits each, this Nasdaq-listed biotech looks like an attractive radar candidate.
For those keeping track — this isn’t the first time this profile has stood out.
It was previously brought into focus earlier this year and followed by a sharp rise of approximately 77% intraday, moving from $1.37 at the open to a high of $2.43 on June 27th.
Take a moment—this is one to consider keeping an eye on:
Autonomix Medical, Inc. (AMIX)
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated.
The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies.
The Autonomix Mission
The mission of Autonomix is to dramatically improve the quality of life for millions by empowering the nerve-targeted treatments of tomorrow.
The company is committed to equipping physicians with innovative tools that enable unparalleled precision in diagnosis and treatment.
As a result, patients can expect more targeted therapies and a renewed sense of hope.
With its groundbreaking technology, Autonomix believes it can enable new procedures that were previously not possible.
Precision Approach to Pain Management
Autonomix Medical, Inc. is a medical device company developing precision nerve-targeted therapies to transform treatment of peripheral nervous system diseases.
The Company’s first-in-class platform technology utilizes a proprietary, catheter-based microchip sensing array that we believe surpasses other sensing technology available today and sets a new standard in neural signal detection.
For the first time ever, the sensing technology enables the ability to detect and differentiate neural signals by combining ultra-high sensitivity with data processing performed directly at the point of detection.
Once target nerves are identified, Autonomix uses its proprietary radio frequency (RF) ablation technology to kill targeted nerves, enabling a precision guided sense, treat and verify approach to addressing a number of disease categories from chronic pain management to hypertension and cardiology.
Autonomix is initially developing its precision nerve-targeted technology for the treatment of pain associated with pancreatic cancer.
Initial results from the Company’s ongoing first-in-human study have shown clinically meaningful and durable pain reduction in the initial phase of the study.
By delivering targeted ablation transvascularly through the vessel wall, Autonomix has demonstrated success in pancreatic cancer pain which opens up the possibility of transformative denervation treatment across a number of disease categories including hypertension, chronic pain, cardiology, pulmonology, and gastroenterology through a single, first-in-class platform technology.
Platform Expansion Opp. Across High-Value Indications
Once validated, the Autonomix platform can extend to a broad range of conditions driven by overactive and dysfunctional nerves:
- Visceral and tumor-related pain
- Hypertension and other cardiovascular conditions
- Abdominal, joint, and lower back pain
- Pulmonary and digestive diseases
- Urinary tract disorders
- Additional organ-specific dysfunctions involving nerve signaling
Wherever the nervous system plays a role, Autonomix has the potential to make an impact. This broad applicability represents a major opp. to improve patient outcomes and generate long-term value for stakeholders.
The Full Autonomix Market Opp. | 
